Search research articles
Contact Us
Filters
Showing results (71-80 of 81) with videos related to
Page
of 9
Sort By:
Journal of Medicinal Chemistry
|
September 6, 2012
The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase α
Timothy P Heffron, Laurent Salphati, Bruno Alicke, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
September 18, 2016
Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma
Laurent Salphati, Bruno Alicke, Timothy P Heffron, et al.
Molecular Cancer Therapeutics
|
October 15, 2011
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway
Jeffrey J Wallin, Kyle A Edgar, Jane Guan, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 4, 2011
Structure-based design of thienobenzoxepin inhibitors of PI3-kinase
Steven T Staben, Michael Siu, Richard Goldsmith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 21, 2012
Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier
Laurent Salphati, Timothy P Heffron, Bruno Alicke, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 9, 2010
Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase
Steven T Staben, Timothy P Heffron, Daniel P Sutherlin, et al.
Journal of Medicinal Chemistry
|
May 14, 2013
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity
Chudi O Ndubaku, Timothy P Heffron, Steven T Staben, et al.
Cancer Discovery
|
September 21, 2021
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Kyung W Song, Kyle A Edgar, Emily J Hanan, et al.
Journal of Medicinal Chemistry
|
January 8, 2016
The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326)
Timothy P Heffron, Robert A Heald, Chudi Ndubaku, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 2, 2013
Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform
Steven T Staben, Chudi Ndubaku, Nicole Blaquiere, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 81) with videos related to
Sort By:
Page
of 9
Journal of Medicinal Chemistry
|
September 6, 2012
The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase α
Timothy P Heffron, Laurent Salphati, Bruno Alicke, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
September 18, 2016
Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma
Laurent Salphati, Bruno Alicke, Timothy P Heffron, et al.
Molecular Cancer Therapeutics
|
October 15, 2011
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway
Jeffrey J Wallin, Kyle A Edgar, Jane Guan, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 4, 2011
Structure-based design of thienobenzoxepin inhibitors of PI3-kinase
Steven T Staben, Michael Siu, Richard Goldsmith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 21, 2012
Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier
Laurent Salphati, Timothy P Heffron, Bruno Alicke, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 9, 2010
Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase
Steven T Staben, Timothy P Heffron, Daniel P Sutherlin, et al.
Journal of Medicinal Chemistry
|
May 14, 2013
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity
Chudi O Ndubaku, Timothy P Heffron, Steven T Staben, et al.
Cancer Discovery
|
September 21, 2021
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Kyung W Song, Kyle A Edgar, Emily J Hanan, et al.
Journal of Medicinal Chemistry
|
January 8, 2016
The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326)
Timothy P Heffron, Robert A Heald, Chudi Ndubaku, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 2, 2013
Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform
Steven T Staben, Chudi Ndubaku, Nicole Blaquiere, et al.
Page
of 9